Three ways you can design better drug trials for schizophrenia therapeutics

To date, no effective drugs have been developed to address cognitive dysfunction in schizophrenia. Here we will highlight the three main methodological challenges which may be contributing to these high failure rates, and propose potential practical solutions to these problems.                                                                                                                                                                                                  

Exploring participant-level trajectories of cognitive performance in patients with schizophrenia

Cambridge Cognition and Boehringer Ingelheim have been investigating cognitive performance among patients with schizophrenia, with a view to improving future pro-cognitive drug trial designs. Our Director of Neuroscience, Dr Kiri Granger, presented the latest findings at ISCTM and SIRS.

Affective face processing in schizophrenia: disorder-specific or transdiagnostic deficit?

Our recent review of meta-analyses concluded that facial emotion recognition deficits are common across a range of psychiatric, neurological and developmental disorders.

Our Senior Scientist, Dr Jack Cotter, presented the latest findings at Schizophrenia International Research Society (SIRS) conference.

Comparing visuospatial associative learning for a middle-aged birth cohort and patients with schizop

Visuospatial memory is extremely heterogeneous in schizophrenia. In a large population study, around a fifth of patients with schizophrenia showed similar errors rates to the top 50% of the general population. Conversely, half of the patients sampled showed substantial impairments. 

Cambridge Cognition announces major contract win and funding award

We're pleased to announce the award of a major new pharmaceutical clinical trial contract and a Digital Health Catalyst grant from Innovate UK.

Join us at SIRS 2018

Cambridge Cognition are attending the Schizophrenia International Research Society Conference (SIRS): 4th - 8th April 2018

How to select sensitive outcome measures in pro-cognitive drug trials for schizophrenia

The outcome measure selected for a pro-cognitive drug trial in schizophrenia must be sensitive enough to detect potentially subtle changes in cognition.

Trial design: 4 ways to improve trials of pro-cognitive drugs in schizophrenia

Discussing the methodological considerations, and suggesting recommendations, for successful pro-cognitive drugs trials in schizophrenia.

Patient recruitment: are you selecting the right patients for schizophrenia clinical trials?

The importance of recruiting patients for pro-cognitive drug trials in schizophrenia on the basis of cognitive dysfunction. 

Improving clinical trials for pro-cognitive drugs in schizophrenia

Introducing a blog-post series to discuss key limitations, and potential improvements, for pro-cognitive drug trials in schizophrenia.

WEBINAR: Overcoming methodological challenges to enhance study success in schizophrenia trials

Dr Kiri Granger, Director of Neuroscience, Cambridge Cognition and Dr Steve Brannan, Chief Medical Officer, ‎Karuna Pharmaceuticals Inc. hosted a webinar on how to improve clinical trial success in schizophrenia.

Using defined inclusion criteria to establish baseline cognitive deficits in CIAS clinical trials

Dr Kiri Granger presented this poster at the International Congress on Schizophrenia Research on the 25th March 2017.

Poster presentation at the International Congress on Schizophrenia Research

Senior Scientist, Kiri Granger, PhD will be presenting a poster at the International Congress on Schizophrenia Research (ICOSR) from the 24th to 28th March.